The key points are temporarily unavailable. You can still read the full Story below.
Main Points
PT Daewoong Pharmaceutical Indonesia has officially launched fexuprazan in Indonesia, introducing a new generation of Potassium-Competitive Acid Blocker (P-CAB) therapy for patients suffering from gastroesophageal reflux disease (GERD). The product launch took place on Friday, September 18, 2026, during the Indonesian Digestive Disease Week (IDDW) held at the Shangri-La Hotel in Jakarta. The event included a scientific symposium focused on the latest developments in P-CAB therapy and the presentation of clinical evidence regarding the treatment. Article source: indoposco.id | Image credit: indoposco.id
PT Daewoong Pharmaceutical Indonesia has officially launched fexuprazan in Indonesia, introducing a new generation of Potassium-Competitive Acid Blocker (P-CAB) therapy for patients suffering from gastroesophageal reflux disease (GERD).
The product launch took place on Friday, September 18, 2026, during the Indonesian Digestive Disease Week (IDDW) held at the Shangri-La Hotel in Jakarta. The event included a scientific symposium focused on the latest developments in P-CAB therapy and the presentation of clinical evidence regarding the treatment.
News Desk is the editorial publishing account for Tringlobe Media News, covering breaking news, public affairs, entertainment, community developments and regional stories across Trinidad and Tobago, the Caribbean and internationally.